In other gynecological malignancies—ovarian cancer, we also observed differences in HIF1A and VEGFA expression levels in a case–control study, but also EPAS1 differed significantly (Englert-Golon et al. 2022). This evidence concerns the gene EPAS1 and ovarian cancer.